consumers. And this spending was especially onerous when one looked into the expenditures not made for improving processing and packaging operations.
In this issue’s story by Steve Barlas, you’ll read about the U.S. Food & Drug Administration’s attempts to stimulate investment in new technology in both processing and packaging by pharma companies because jawboning the issue hasn’t worked. And next month, Steve will report on the plans (or lack of them) of pharma companies to deal with counterfeit drugs, not only overseas but domestically, too.
